$503606
Our Philanthropic and Educational Contributions to our Community

Your support is crucial in helping us continue our mission to improve the health of our community.

OUR MISSION

Since 2003, Midwest Cardiovascular Research & Education Foundation nurses, cardiologists, and community leaders have committed themselves to supporting research and education that seek to improve cardiovascular health and clinical outcomes for the people and communities we serve.

 


 

READ MORE

OUR RESEARCH

Midwest Cardiovascular Research and Education Foundation collaborates on cutting-edge national and global clinical trials. We aim to advance the health and cardiovascular care of patients and to broaden evidence-based practice.

 

 


 

READ MORE

CURRENT RESEARCH TRIALS

VICTORION I PREVENT

This study is testing if a drug called inclisiran can prevent major heart problems in people at high risk who haven’t had a major cardiovascular event before. Participants receive either inclisiran or a placebo through a shot on Day 1, Day 90, and every six months. The study aims to see if inclisiran can reduce the risk of cardiovascular death, heart attacks, strokes, and urgent heart procedures compared to a placebo.

PREVAIL

The PREVAIL study is a phase 3 clinical trial investigating the effect of a drug called Obicetrapib in patients with Atherosclerotic Cardiovascular Disease (ASCVD). These patients are already on the highest possible doses of other lipid-lowering therapies but still need better control of their condition. This study is designed to see if Obicetrapib can further reduce the risk of serious heart-related events like heart attacks, strokes, and the need for emergency heart surgeries compared to a placebo.

COMPLETE TAVR

The COMPLETE TAVR study is a clinical trial comparing two strategies for patients with severe aortic stenosis and concomitant coronary artery disease (CAD) undergoing transcatheter aortic valve replacement (TAVR). One group will receive complete revascularization with staged percutaneous coronary intervention (PCI) using drug-eluting stents, while the other group will receive only medical therapy. The trial aims to determine if PCI can reduce the risk of cardiovascular death, heart attacks, and hospitalizations compared to medical management alone.

BalanceD-HF

The BalanceD-HF study is a Phase III, international, multi-center, randomized, double-blind, parallel-group, double-dummy, active-controlled, event-driven trial. It aims to evaluate the effect of the combination of balcinrenone and dapagliflozin versus dapagliflozin alone on cardiovascular death and heart failure (HF) events in patients with chronic HF and impaired kidney function who have recently experienced an HF event. Patients will be randomly assigned to receive one of the following treatments: balcinrenone/dapagliflozin 15 mg/10 mg, balcinrenone/dapagliflozin 40 mg/10 mg, or dapagliflozin 10 mg, along with corresponding placebos. The study duration is estimated to be 22 months, and it will be conducted at around 700 sites globally.

EDUCATION

 

Education through research: Midwest Cardiovascular Research & Education Foundation does this through clinical trials.


READ MORE

Annual Continuing Medical Education Event

Each year, we host an expert speaker to highlight new and cutting edge topics. It is our goal that this knowledge will enhance the care and wellbeing of our patients and community.

Summer Externship Program

Each summer, we invite an area high school graduate or college student to work closely with us. These externs gain a deeper understanding of the conduct of clinical research and the care of patients within clinical trials. They gain exposure to cardiovascular care in the inpatient and outpatient settings. These students have gone on to careers in fields such as medicine, clinical psychology, nursing, and clinical research.

CPR Training

We provide free CPR training to area non-profit organizations, including the use of Automated External Defibrillators (AED’s). Early intervention in cardiac arrest is the key to survival.